Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
Learn about treatment options, treatment failure, associated adverse effects and more.
Choose from the criteria below to find an activity that fits you best.
Note: If you attended the live CE activity AND received CE credit (i.e.
a pharmacist CE statement of credit with ACPE UAN 0221-9999-19-504-L01-P), you are
NOT allowed to also receive credit for this home-study on-demand web activity.
|Co-produced by ProCE and the Society of Infectious Diseases Pharmacists (SIDP).|
Globally, an overabundance of inappropriate antibiotic use in factories, farms,
improper use in people, and lack of consistent stewardship measures in health-systems
have compounded measures to address the rising bacterial resistance crisis. Multidrug-resistant
(MDR) gram-negative bacteria are particularly challenging for infectious diseases
professionals to address due to increased mechanisms to evade destruction and appearance
in the most vulnerable patients. Often emerging in the health-system setting, and
thus in the critically ill population, MDR gram-negative infections require immediate
attention. The Centers for Disease Control and Prevention (CDC) declared carbapenem-resistant
Enterobacteriaceae (CRE) an urgent threat – an entire class of bacteria which
have developed multiple enzymes to circumvent destruction by carbapenems.
This activity will review the current epidemiological resistance patterns of MDR gram-negative bacteria. Attendees will understand treatment strategies and patient selection criteria for the management of MDR gram-negative infections, including newly approved therapies and emerging treatment data. A discussion on incorporation of antimicrobial stewardship with a special focus on preserving newer therapies will provide additional insight into potential protocol development.
The target audience for this activity includes clinical pharmacists, community pharmacists, specialty pharmacists, and managed care professionals. At the completion of this activity, the participant will be better able to:
Samuel L. Aitken, PharmD, MPH, BCIDP
Clinical Pharmacy Specialist, Infectious Diseases
Director, PGY2 Infectious Diseases Pharmacy Residency
Division of Pharmacy
The University of Texas MD Anderson Cancer Center
Erin K. McCreary, PharmD, BCPS, BCIDP
Infectious Diseases Clinical Pharmacist
University of Pittsburgh Medical Center
Release Date: 12-10-2019
Expiration Date: 1-15-2021
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-504-H01-P has been assigned to this home study knowledge-based activity (initial release date 12-10-19). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. Statements of completion will be issued online at www.ProCE.com and proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Aitken has received research grant funding from Melinta Therapeutics and Merck, and has served as an advisory board member for Merck, Paratek, and Shionogi. Dr. McCreary has served as a consultant for Cidara Therapeutics. A portion of grant funds received by ProCE from Merck will be used to compensate the faculty for this presentation.
This activity is supported by an educational grant from Merck.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.